|
(Health-NewsWire.Net, May 02, 2015 ) This report provides a comprehensive overview of the size of cancer immunotherapy market, the segmentation of the market, key players and the vast potential of therapies that are in clinical trials. Oncologic therapeutics cannot cure cancer and yet in 2014, the overall market for cancer therapeutics stood at about $84.3 billion.
View report details with TOC at: http://www.researchmoz.us/global-and-usa-cancer-immunotherapy-market-analysis-to-2020-antibody-drug-conjugates-adcs-bispecific-monoclonal-antibodies-cancer-vaccines-cytokines-interferons-chimeric-antigen-receptor-car-t-cell-therapy-pd-1pd-l1-inhibitors-dendriti-report.html
Any drug that can provide a reasonable survival of more than five years for the cancer patients can achieve a blockbuster status. Within the cancer therapeutics, the immunotherapeutic drugs have gained worldwide acceptance, because they are targeted drugs targeting only the cancer cells. Today, cancer immunotherapy drugs have captured nearly 50% of the overall oncology drugs market, generating about $41.0 billion in 2014 alone.
This report describes the evolution of such a huge market in 11 chapters supported by 114 tables and 41 figures over 256 pages:
An overview of cancer immunotherapy that includes: monoclonal antibodies, cancer vaccines and non-specific cancer immunotherapies.
Focus on current trends in cancer immunotherapies that include: anti-PD-1 drugs, Dendritic cell vaccines, T-cell therapies and cancer vaccines.
Insight into the challenges faced by drug developers, particularly about the success vs. failure ratios in developing cancer immunotherapy drugs.
Descriptions about 23 cancer immunotherapeutics approved and used as targeted drugs (some of these products have already been withdrawn from the market).
Insight into the various immunotherapeutics available for specific cancer types.
Description and data for the prevalence of cancer types that are addressed by cancer immunotherapeutics.
Overall global cancer therapeutics market, leading market players and the bestselling cancer drugs.
Detailed account of the market for cancer immunotherapeutics by geography, indication, company and individual drugs.
Profiles, marketed products and products in pipeline of 76 companies that are mostly located in the U.S. and Europe.
Summary table to identify the category of immunotherapy drug offered by the 76 companies.
Request a REPORT SAMPLE at: http://www.researchmoz.com/enquiry.php?type=sample&repid=272900
The global market for cancer immunotherapy by the following sub-categories are presented:-
By Segment (Monoclonal Antibodies, Cancer Vaccines, Non-Specific Therapies, Checkpoint Inhibitors)
By Product Segment (Antibody Drug Conjugates (ADCs), Bispecific Monoclonal Antibodies, Cytokines, Interferons, Chimeric Antigen Receptor (CAR) T-Cell Therapy, PD-1/PD-L1 inhibitors, Dendritic Cells, Adopted Cell Therapy (ACT) & IDO Inhibitors
By Company (e.g Amgen, Merck, Eli Lilly, GlaxoSmithKline, Janssen, Genentech, Roche, Bristol Myers Squibb)
Browse More related reports at: http://www.researchmoz.us/biotechnology-market-reports-30.html
Key Questions Answered in this Report:-
What are the three types of cancer immunotherapies?
What are the immunotherapies approved between 1986 and 2014?
What are the monoclonal antibodies (MAbs) approved by FDA to treat different types of cancers?
What are naked MAbs and how many of them have been approved by FDA?
What are antibody-drug conjugates (ADCs) and how many of them are available in the market?
What are the common cytotoxic “warheads” used in ADCs?
What are the important clinical assets in ADCs?.............................
About Us:
ResearchMoz is the one stop online destination to find and buy market research reports. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. We provide the market context, competitor insight and future trends needed for strategic planning.
Researchmoz Global Pvt.Ltd
Researchmoz
+1-518-618-1030
sales@researchmoz.us
Source: EmailWire.Com 
|
